Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 14Ovarian Neoplasms 12Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lymphoma 3Lung Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Hereditary Breast and Ovarian Cancer Syndrome 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Zollinger-Ellison Syndrome 1Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Neoplasm × veliparib × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡